8-K
filed September 29, 2021, 7:59 PM ET
ticker JSPR
CIK 0001788028
M&A
confidence high
sentiment neutral
materiality 0.85
Amplitude Healthcare completes business combination with Jasper Therapeutics; begins trading as JSPR
Jasper Therapeutics, Inc.
- Redemption of 9,262,099 AMHC shares for $92.7M; PIPE of $100M from 10M shares at $10.00 each.
- Old Jasper equity valued at $275M; post-closing shares: 36.5M voting, 1.3M non-voting, 2.7M options.
- Sponsor deposited 1,050,000 earnout shares subject to price thresholds of $11.50, $15, $18 VWAP.
- New company renamed Jasper Therapeutics, Inc.; tickers JSPR (common) and JSPRW (warrants) on Nasdaq.
- Amended registration rights agreement with 180-day lock-up; indemnification agreements with directors/officers.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Vishal Kapoor departed as Executive Officer at Jasper Therapeutics, Inc..
- Action
- ceased serving
- Role
- Executive Officer
Exact text from the filing
each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bala Venkataraman departed as Executive Officer at Jasper Therapeutics, Inc..
- Action
- ceased serving
- Role
- Executive Officer
Exact text from the filing
each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kenneth Clifford departed as Executive Officer at Jasper Therapeutics, Inc..
- Action
- ceased serving
- Role
- Executive Officer
Exact text from the filing
each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William Lis was appointed as President, Chief Executive Officer and Executive Chairman at Jasper Therapeutics, Inc..
- Action
- appointed
- Role
- President, Chief Executive Officer and Executive Chairman
Exact text from the filing
William Lis President, Chief Executive Officer and Executive Chairman of the New Jasper Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin N. Heller, M.D. was appointed as Executive Vice President, Research and Development at Jasper Therapeutics, Inc..
- Action
- appointed
- Role
- Executive Vice President, Research and Development
Exact text from the filing
Kevin N. Heller, M.D. Executive Vice President, Research and Development
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeet Mahal was appointed as Chief Financial and Business Officer and Corporate Secretary at Jasper Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Financial and Business Officer and Corporate Secretary
Exact text from the filing
Jeet Mahal Chief Financial and Business Officer and Corporate Secretary
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.